Gain Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Gain Therapeutics

09/05/2025 16:23

Gain Therapeutics Inc GANX.OQ GANX.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Bethesda Maryland-based  company is expected to report revenue of $25 thousand, according to the mean estimate from 4 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Gain Therapeutics Inc is for a loss of 18 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00‚Äč, above‚Äč its last closing price of $2.03. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.17
-0.18
-0.11
Beat
40
Sep. 30 2024
-0.22
-0.21
-0.17
Beat
20.9
Jun. 30 2024
-0.19
-0.20
-0.42
Missed
-110‚Äč
Mar. 31 2024
-0.29
-0.29
-0.22
Beat
24.8
‚Äč‚ÄčDec. 31 2023
-0.30
-0.32
-0.36
Missed
-11.6
Sep. 30 2023
-0.45
-0.45
-0.37
Beat
17‚Äč
Jun. 30 2023
-0.32
-0.31
-0.62
Missed
-101.6
Mar. 31 2023
-0.40
-0.39
-0.43
Missed
-9.3

This summary was machine generated May 9 at 15:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)